CDK2 and cancer: Aneuploidy is a hallmark of cancer.1 This can be targeted pharmacologically by inhibition of CDK2 as with CYC065-treatment48 and by other drugs, as reviewed.35 Our prior work found in vivo CDK2 inhibitor treatments of syngeneic mouse lung cancer models (as well as in patient derived lung cancer xenografts and athymic mouse lung cancer xenografts) that statistically-significant reductions of tumor growth followed CDK2-treatment, but residual tumors were detected.48,49